Commercial launch of AlbuFree DX recombinant human albumin by Proliant Health & Biologicals using Dyadic's production platform, with Dyadic eligible to receive a share of profits from product salesExp ...

Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic’s production ...

In academic and industrial protein research, speed, accuracy, and accessibility are essential. After purifying proteins using ...

After Decades of Global Failures, Kraig Poised to Deliver First High-Performance Recombinant Breakthrough DENVER, ...

For research scientists and laboratory professionals navigating increasingly complex experimental challenges, access to ...

Q16W dosing interval; Furthermore, nearly 60% of the participants held the potential to extend the dosing interval to Q20W.

Can healthy dividends continue from CSL? The post Here's the dividend forecast out to 2030 for CSL shares appeared first on The Motley Fool Australia.

As cell therapy advances toward clinical reality, iPSC-derived cellular products, in vivo reprogramming strategies, and ...

AAA Biotech’s Validated Antibodies, Recombinant Proteins, and ELISA Kits Power Breakthrough Research Across Drug ...

To address these critical safety requirements, BETMAT Biotechnology LLC has released a specialized operational guide focused on Reliable Endotoxin Testing For Injectable Pharmaceuticals, a systematic ...

The biotechnology company, which develops genetically engineered silkworms, says it is moving toward commercial production of ...

The U.S. Pharmacopeia has approved synthetic alternatives to horseshoe crab blood for bacterial endotoxin testing, a ...